First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis.

ABSTRACT:

Background

Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for multiple sclerosis (MS). While its efficacy has been attributed to early and sustained B cell depletion, emerging evidence suggests a broader immunomodulatory profile.

Objectives

To investigate temporal dynamics of OCR-induced immune modulation in MS by analyzing pathway enrichment score changes in transcriptomic data from peripheral blood mononuclear cells (PBMCs) at early (2 weeks) and late (6 months) timepoints following treatment initiation.

Methods

We analyzed publicly available microarray data (GSE228330) from PBMCs of 15 MS patients treated with OCR. Immune cell subpopulations were estimated using CIBERSORTx with the LM22 signature matrix. Gene Set Variation Analysis (GSVA) w

SUBMITTER: Abbadessa G 

PROVIDER: S-EPMC12357791 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature